Down-regulation of human topoisomerase IIα correlates with altered expression of transcriptional regulators NF-YA and Sp1

Anti-Cancer Drugs

Volumn 15, Issue 4, 2004, Pages 357-362

  Allen, Kirsty A ^a   Williams, Amram O ^a   Isaacs, Richard J ^b   Stowell, Kathryn M ^a  

^a MASSEY UNIVERSITY   (New Zealand)

^b MidCentral Health   (New Zealand)

Author keywords

Breast cancer cell lines; Doxorubicin; Drug resistance; Topoisomerase II; Transcriptional regulation

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF YA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CELL; CANCER CELL CULTURE; CELL ASSAY; CLONE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; CCAAT-BINDING FACTOR; CELL DIVISION; CELL EXTRACTS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOWN-REGULATION; DOXORUBICIN; HUMANS; IMMUNOBLOTTING; P-GLYCOPROTEIN; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 1942517369     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200404000-00008     Document Type: Article

References (33)

1. Wang JC, Liu LF. DNA replication: topological aspects and the roles of DNA topoisomerases. In: Cozzarelli NR, Wang JC (editors): DNA Topology and its Biological Effects, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1990, pp. 321-340.
2. Topcu Z. DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 2001; 26:405-416.
3. Bakshi RP, Galande S, Muniyappa K. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol 2001; 36:1-37.
4. Austin CA, Fisher LM. DNA topoisomerases: enzymes that change the shape of DNA. Sci Progress 1990; 74:147-162.
5. McPherson JP, Deffie AM, Jones NR, Brown GA, Deuchars KL, Goldenberg GJ. Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha. Anticancer Res 1997; 17:4243-4252.
6. Towatari M, Adachi K, Marunouchi T, Saito H. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. Br J Haematol 1998; 101:548-551.
7. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Drug resistance associated with altered DNA topoisomerase II. Adv Enz Reg 1993; 33: 113-127.
8. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIbeta isoform. Biochemistry 1991; 30:9953-9961.
9. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 1993; 32:103-108.
10. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and toposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Clin Cancer Res 1998; 4:1005-1012.
11. Mo YY, Wang Q, Beck WT. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3. Cancer Res 1997; 57:5004-5008.
12. Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer 2001; 85:747-751.
13. Hochhauser D, Stanway CA, Harris AL, Hickson ID. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIa gene. J Biol Chem 1992; 267:18961-18965.
14. Kubo T, Kohno K, Ohga T, Taniguchi K, Kawanami K, Wada M, et al. DNA topoisomerase IIa gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res 1995; 55:3860-3864.
15. Isaacs RJ, Harris AL, Hickson ID. Regulation of the human topoisomerase IIa gene promoter in confluence-arrested cells. J Biol Chem 1996; 271:16741-16747.
16. Herzog CE, Zwelling LA. Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoter. Biochem Biophys Res Commun 1997; 232:608-612.
17. Magan N, Szremska A, Isaacs RJ, Stowell KM. Modulation of the human topoisomerase IIalpha promoter by members of the Sp1 and NF-Y families of transcription factors. Biochem J 2003; 374:723-729.
18. Wang H, Jiang Z, Wong YW, Dalton WS, Futscher BW, Chan VT. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Biophys Res Commun 1997; 237: 217-224.
19. Morgan SE, Beck WT. Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Mol Pharmacol 2001; 59:203-211.
20. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis V, et al. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, EAR-3. J Biol Chem 1992; 267: 15849-15860.
21. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993; 213:414-421.
22. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase II alpha/beta, cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 1995; 89:356-563.
23. Davis J. Basic Cell Culture: A Practical Approach. Oxford: IRL Press at Oxford University Press; 1994.
24. Herbomel P, Bourachot B, Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 1984; 39:653-662.
25. Withoff S, Smit EF, Meersma GJ, van den Berg A, Timmer-Bosscha H, Kok K et al. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest 1994; 71:61-66.
26. Tsutsui K, Sano K, Kikuchi A, Tokunaga A. Involvement of DNA topoisomerase IIbeta in neuronal differentiation. J Biol Chem 2001; 276:5769-5778.
27. Kimura K, Saijo M, Ui M, Enomoto T. Growth state-and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M-phase. J Biol Chem. 1994; 269:1173-1176.
28. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12:450-458.
29. Wurzer G, Herceg Z, Wesierska-Gadek J. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res 2000; 60:4238-4244.
30. Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA. Life Sci 2000; 67:2117-2124.
31. Heenan M, O'Driscoll L, Cleary I, Connolly L, Clynes M. Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance. Int J Cancer 1997; 71:907-915.
32. Marziali G, Perrotti E, Ilari R, Coccia EM, Mantovani R, Testa U, et al. The activity of the CCAAT-box binding factor NF-Y is modulated through the regulated expression of its A subunit during monocyte to macrophage differentiation: regulation of tissue-specific genes through a ubiquitous transcription factor. Blood 1999; 93:519-526.
33. Larsen AK, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1998; 1400:257-274.